WO2004082675A1 - Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate - Google Patents
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate Download PDFInfo
- Publication number
- WO2004082675A1 WO2004082675A1 PCT/JP2004/003589 JP2004003589W WO2004082675A1 WO 2004082675 A1 WO2004082675 A1 WO 2004082675A1 JP 2004003589 W JP2004003589 W JP 2004003589W WO 2004082675 A1 WO2004082675 A1 WO 2004082675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food
- patient
- carbonyl
- ethylbutyl
- phenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 230000001965 increasing effect Effects 0.000 title claims abstract description 21
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 114
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 53
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 50
- FFAADXOKPZHULO-UHFFFAOYSA-N 2-methylpropanethioic s-acid Chemical compound CC(C)C(S)=O FFAADXOKPZHULO-UHFFFAOYSA-N 0.000 claims description 49
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 39
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 36
- 230000036470 plasma concentration Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 3
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 3
- 241001024304 Mino Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 description 124
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 1- (2-ETHYLBUTYL) CYCLOHEXYL Chemical class 0.000 description 5
- 235000021152 breakfast Nutrition 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 230000009246 food effect Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000006194 liquid suspension Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- TECHNICAL FIELD This invention is directed to methods for the treatment or prophylaxis of cardiovascular disorders.
- Cholesteryl ester transfer protein is a plasma protein that facilitates the movement of cholesteryl esters and triglycerides between various lipoproteins in the blood.
- the movement of cholesteryl ester from HDL to LDL by CETP has the effect of lowering HDL cholesterol and increasing LDL cholesterol.
- Inhibition of CETP activity has been shown to effectively modify plasmid HDL/LDL ratios by elevating plasma HDL cholesterol and lowering plasma LDL cholesterol.
- This invention provides such a method, as well as a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[l ⁇ (2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug to improve bioavailability.
- the invention provides a method of increasing the bioavailability of the active form of5'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate in a patient receiving 5'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate therapy wherein 5'-[2-([[l -(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate is contained in a pharmaceutical composition, which method comprises orally administering a therapeutically effective amount of the drug to the patient with food.
- the increased bioavailability of the active form can be evidenced by an increase in the maximum plasma concentration of the active form.
- the invention also provides a method of increasing the extent of absorption of that active form of 5'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate as measured by the concentration of the active form attained in the blood stream over time of a patient receiving the drug in an oral dosage form.
- This method comprises orally administering a therapeutically effective amount of S-[2-([[[l-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate to the patient with food.
- the invention further provides a method for decreasing the activity of cholesteryl ester transfer protein (CETP) in a patient.
- the method comprises orally administering a therapeutically effective amount of S-[2-([[l-(2- ethylbutyl)cyclohexyI]carbonyl]amino)phenyl] 2-mefhylpropanethioate to the patient with food.
- the invention additionally provides a method for the treatment or prophylaxis of a cardiovascular disorder in a patient.
- the method comprises orally administering S-[2-([[l- (2 -ethylbutyl)cyclohexyl] carbonyl] amino)phenyl] 2-methylpropanethioate to the patient with food.
- the invention provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[l-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container.
- the prescribing information includes advice to a patient regarding the administration of S-[2- ([[l-(2-etl ⁇ ylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate with food.
- Figure 1 is a linear plot of the geometric mean plasma concentrations ( ⁇ g mL) of the active form of S-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate over 36 hours in Caucasian male patients, who were orally administered 900 mg of »S'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate with food or without food.
- Figure 2 is a semi-logarithmic plot of the geometric mean plasma concentrations ( ⁇ g/mL) of the active form of 5'-[2-([[l-(2-ethylbutyl)cyelohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate over 36 hours in Caucasian male patients, who were orally administered 900 mg of S-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate with food or without food.
- Figure 3 is plot of the mean changes from baseline (pre-dose) in CETP activity over 24 hours in Caucasian male patients, who were orally administered 900 mg of S-[2- ([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate with food or without food.
- Figure 4 is a plot of mean CETP activities and mean plasma concentrations of the active form of ,S'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate over 24 hours in Caucasian male patients following the oral administration of 900 mg of 5'-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate with food.
- Figure 5 is a plot of mean CETP activities and mean plasma concentrations of the active form of S- [2-([[l-(2-ethylbutyl)cyclohexyl] carbonyl] amino)phenyl] 2- methylpropanethioate over 24 hours in Caucasian male patients following the oral administration of 900 mg of S-[2-([ [ 1 -(2-ethylbutyl)cyclohexyl] carbonyl] amino)phenyl] 2- methylpropanethioate without food.
- the invention is directed to methods for improving the effectiveness of the administration of S-[2-([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate (herein referred to as Compound I) and/or for the treatment or prophylaxis of certain cardiovascular disorders.
- cardiovascular disorders include, but are not limited to, cardiovascular disease, coronary heart disease, coronary artery disease, hypoalphalipoproteinemia (low levels of HDL cholesterol), hypercholesterolemia, and atherosclerosis.
- Additional disorders that may be treated or prevented by the inventive methods include, but are not limited to, hyperlipidemia, hypertension, hypertriglyceridemia, and hyperlipidoproteinemia.
- Compound I has the following structural formula:
- Compound I can be administered to patients in a regimen that increases the therapeutic effectiveness of Compound I to such patients.
- Compound I when orally administered with food, Compound I exhibits increased bioavailability of the active form of Compound I in patients.
- the invention provides a method of increasing the bioavailability of the active form of Compound I in a patient comprising administering to the patient a therapeutically effective amount of Compound I with food.
- bioavailability generally means the rate and extent to which the active ingredient, or active form thereof, is absorbed from a drug product and becomes available at the site of action. See U.S. Code of Federal Regulations, Title 21, Part 320.1 (2001 ed.).
- bioavailability relates to the processes by which the active ingredient is released from the oral dosage form, e.g., a tablet, converted to the active form (if the active ingredient is not already the active form), and moved to the site of action, e.g., absorbed into the systemic circulation.
- Compound II is hydrolyzed in plasma, the liver, and/or the small intestine to form S-[2([[l-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] thiol (herein referred to as Compound II).
- R-SH low molecular weight thiol components
- Prot-SH high molecular weight thiol components
- peptides and proteins e.g., enzymes and cell membranes
- the invention also contemplates the administration of other compounds that will yield the active form of Compound I, i.e., other prodrugs of the active form of Compound I.
- prodrugs for example, can be compounds that have different mercapto- protecting groups, but that still result in the formation of the active form of Compound I (e.g., Compound II) in the body of a patient (i.e., in vivo).
- mercapto-protecting groups refers to commonly used mercapto-protecting groups (e.g., as described in Wolman, The Chemistry of the Thiol Group, D. Patai, Ed., Wiley-Interscience, New York, 1974).
- Any organic residues that can be dissociated in vivo may be used without particular restriction. Examples of particularly suitable mercapto-protecting groups are described in U.S. Patent 6,426,365.
- the invention further contemplates the administration of Compound I' (wherein R' signifies an organic residue other than an isopropyl group) so as to yield the active form of Compound I.
- the term "with food” is defined to mean, in general, the condition of having consumed food during the period between from about 1 hour prior to the administration of Compound I to about 2 hours after the administration of Compound I.
- the food is a solid food with sufficient bulk and fat content that it is not rapidly dissolved and absorbed in the stomach. More preferably, the food is a meal, such as breakfast, lunch, or dinner.
- Compound I is administered any time of day with food.
- the food can be consumed at any time during the period between from about 1 hour prior to the administration of Compound I to about 2 hours after the administration of Compound I.
- the food can be consumed within the time period of about 1 hour, about 45 minutes, about 30 minutes, about 15 minutes, about 10 minutes, or about 5 minutes prior to , the administration of Compound I.
- the food can be consumed within the time period of about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 1.25 hours, about 1.5 hours, about 1.75 hours, or about 2 hours after the administration of Compound I.
- the administration of Compound I to the patient is immediately after the consumption of food (e.g. within about 1 minute after food consumption) up to about 1 hour after food consumption.
- Compound I is administered at substantially the same time as the consumption of the food.
- a suitable dose of a therapeutically effective amount of Compound I for administration to a patient will be between approximately 100 mg to about 1800 mg per day.
- a suitable dose is preferably about 300 mg to about 900 mg per day.
- a preferred dose is about 600 mg per day.
- the effective daily dose of Compound I may be administered as two, three, four, five, six, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Each such sub-dose contains a therapeutically effective amount of Compound I.
- Compound I may be administered with food at multiple times per day or, alternatively, once per day. When administered at multiple times throughout the day, each individual dose contains a therapeutically effective amount of Compound I.
- Compound I is administered with food once per day.
- the term "unit dosage form" is defined to refer to the form in which Compound I is administered to the patient.
- the unit dosage form can be, for example, a pill, capsule, or tablet.
- the unit dosage form is a tablet.
- the typical amount of Compound I in a unit dosage form useful in the invention is about 100 mg to about 1800 mg, preferably about 100 mg to about 900 mg (e.g., about 100 mg to about 300 mg).
- the unit dosage form comprises about 300 mg of Compound I and is in the fo ⁇ n of a tablet.
- two or three tablets, each of which comprises about 300 mg of Compound I are administered to the patient once per day (i.e., a total dose per day of about 600 mg or about 900 mg, respectively).
- the increased bioavailability of the active form of Compound I to a patient receiving Compound I therapy can be evidenced in any suitable manner.
- the oral administration of Compound I with food results in an increased bioavailability of the active form of Compound I as evidenced by an increase in the maximum plasma concentration of the active form of Compound I as compared to the administration of Compound I without food.
- Compound I desirably is provided to a patient in a container associated with prescribing info ⁇ nation that advises the patient to orally administer Compound I with food and desirably also explains that doing so will increase the bioavailability of the active form of Compound I.
- Compound I preferably is provided to a patient in a container associated with prescribing information that advises the patient that the administration of the dose of Compound I in a pharmaceutical composition with food results in an increase in the extent of absorption of the active form of Compound I as reflected by an increase in the maximum plasma concentration of the active form of Compound I as compared to the administration of the drag under fasted conditions.
- the invention also provides a method of increasing the extent of absorption of the active form of Compound I as measured by the active form concentration attained in the blood stream over time in a patient in need of a therapeutic effect thereof.
- This method comprises orally administering to a patient a therapeutically effective amount of Compound I in a pharmaceutical composition with food.
- the active form concentration in the blood stream is measured as the plasma concentration ( ⁇ g/mL) of the active form of Compound I.
- Pharmacokinetic parameters involved in determining the plasma concentration include the maximum observed plasma concentration (C max ), area under the plasma concentration time curve (AUC) from time zero up to the last quantifiable concentration (AUCo-tz), and AUC from time zero to infinity (AUC o- ⁇ ).
- Administering Compound I to a patient with food increases the bioavailability of the active form as measured by increased values of one or more (and desirably all) of the aforesaid pharmacokinetic parameters, when compared to administration of the drug under fasted conditions.
- the invention further provides a method for decreasing the activity of cholesteryl ester transfer protein (CETP) in a patient, which comprises orally administering a therapeutically effective amount of Compound I to the patient with food.
- CETP cholesteryl ester transfer protein
- the invention provides a method for the treatment or prophylaxis of a cardiovascular disorder in a patient comprising administering Compound I to the patient, which comprises orally administering a therapeutically effective amount of Compound I to the patient with food.
- cardiovascular disease cardiovascular disease
- coronary heart disease coronary artery disease
- hypoalphalipoproteinemia low levels of HDL cholesterol
- hypercholesterolemia atherosclerosis
- Additional disorders which may be treated or prevented by the inventive method include, but are not limited to, hyperlipidemia, hypertension, hypertriglyceridemia, and hyperlipidoproteinemia.
- Compound I may be administered for therapy to a patient in any conventional manner. While it is possible for Compound I to be administered as the raw chemical, it is preferably administered as a pharmaceutical composition.
- Such pharmaceutical compositions comprise Compound I with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents and/or components.
- the carriers or excipients must be acceptable in the sense of being compatible with the other ingredients and not deleterious to the recipient thereof.
- Examples of carriers or excipients for oral administration include cornstarch, lactose, magnesium stearate, talc, microcrystalline cellulose, stearic acid, povidone, crospovidone, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose (e.g., low substituted hydroxypropyl cellulose), hydroxypropylmethyl cellulose (e.g., hydroxypropylmethyl cellulose 2910), and sodium lauryl sulfate.
- cornstarch lactose, magnesium stearate, talc, microcrystalline cellulose, stearic acid, povidone, crospovidone, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose (e.g., low substituted hydroxypropyl cellulose), hydroxypropylmethyl cellulose (e.g., hydroxypropylmethyl cellulose 2910), and sodium lauryl sulfate.
- hydroxypropyl cellulose e.g
- compositions can be prepared by any suitable method, such as those methods well known in the art of pharmacy, for example, methods such as those described in Gennaro et al., Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Co., 1990), especially Part 8: Pharmaceutical Preparations and their Manufacture.
- Such methods include the step of bringing into association Compound I with the carrier or excipient and optionally one or more accessory ingredients.
- accessory ingredients include those conventional in the art, such as, fillers, binders, diluents, disintegrants, lubricants, colorants, flavoring agents, and wetting agents.
- the pharmaceutical compositions can provide controlled, slow release, or sustained release of the Compound I over a predetermined period of time.
- the controlled, slow release, or sustained release of the therapeutic compound can provide for a concentration of the active form of Compound I to be maintained in the bloodstream of the patient for a longer period of time than with conventional formulations.
- Such pharmaceutical compositions include coated tablets, pellets, and capsules, as well as dispersions of the therapeutic compound in a medium that is insoluble in physiologic fluids or where the release of the therapeutic compound follows degradation of the pharmaceutical composition due to mechanical, chemical, or enzymatic activity.
- the pharmaceutical composition in the context of the invention can be, for example, in the form of a pill, capsule, or tablet, each containing a predetermined amount of Compound I and preferably coated for ease of swallowing, in the form of a powder or granules, or in the form of a solution or suspension.
- the pharmaceutical composition is in the form of a tablet comprising Compound I (or a prodrug of the active fo ⁇ n of Compound I) and the components of the tablet utilized and described in the Examples herein.
- fine powders or granules may contain diluting, dispersing, and or surface active agents and may be present, for example, in water or in a syrup, in capsules or sachets in the dry state, or in a nonaqueous solution or suspension wherein suspending agents may be included, or in tablets wherein binders and lubricants may be included.
- Components such as sweeteners, flavoring agents, preservatives (e.g., antimicrobial preservatives), suspending agents, thickening agents, and/or emulsifying agents also may be present in the pharmaceutical composition.
- the formulation can contain Compound 1 and purified water.
- Optional components in the liquid solution or suspension include suitable sweeteners, flavoring agents, preservatives (e.g., antimicrobial preservatives), buffering agents, solvents, and mixtures thereof.
- suitable sweeteners e.g., peppermint, famame, famame, famame, famame, famame, famame, famame, famame, famame, fame, fame, fame, fambame, fame, fambame, fame, fame, fame, fambame, fambame, fame, fame, fame, fame, fame, fame, fame, fame, fame, fame, fame, fame, fame, fame, f
- Suitable sweeteners include, for example, saccharin sodium, sucrose, and mannitol. A mixture of two or more sweeteners optionally may be used. The sweetener or mixtures thereof are typically present in an amount of from about 0.001% to about 70% by weight of the total composition. Suitable flavoring agents may be present in the pharmaceutical composition to provide a cherry flavor, cotton candy flavor, or other suitable flavor to make the pharmaceutical composition easier for a patient to ingest. The flavoring agent or mixtures thereof are typically present in an amount of about 0.0001% to about 5% by weight of the total composition.
- Suitable preservatives include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride.
- a mixture of two or more preservatives optionally may be used.
- the preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition.
- Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. A mixture of two or more buffering agents optionally may be used. The buffering agent or mixtures thereof are typically present in an amount of about 0.001% to about 4% by weight of the total composition.
- Suitable solvents for a liquid solution or suspension include, for example, sorbital, glycerin, propylene glycol, and water. A mixture of two or more solvents optionally may be used.
- the solvent or solvent system is typically present in an amount of about 1% to about 90% by weight of the total composition.
- Oral delivery methods are often limited by chemical and physical barriers imposed by the body, such as the varying pH in the gastrointestinal tract, exposure to enzymes, and the impermeability of the gastrointestinal membranes.
- the oral administration of the pharmaceutical composition may also include the co-administration of adjuvants.
- nonionic surfactants such as polyoxyethylene oleyl ether and n- hexadecyl polyethylene ether can be administered with or incorporated into the pharmaceutical composition to artificially increase the permeability of the intestinal walls.
- Enzymatic inhibitors also can be administered with or incorporated into the pharmaceutical composition.
- the invention provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of Compound I and a pharmaceutically acceptable carrier, prescribing information, and a container.
- the prescribing information can be prescribing information conforming to the methods of the invention and/or as otherwise discussed herein.
- the prescribing information preferably includes advice to a patient regarding the administration of Compound I with food, especially to improve the bioavailability of the active form of Compound I.
- EXAMPLE 1 The effect of food on Compound I absorption in patients was identified in a study designed to compare the bioavailability of 900 mg of Compound I orally administered to Caucasian male volunteers with and without food.
- each of six subjects received Compound I at a dose level of 900 mg in each of two treatment periods, once with food (after a standard breakfast) and once in the fasted state. There was a minimum of 7 days between each treatment period. This interval of 7 days between treatments was considered appropriate for eliminating any within-subject carryover effects.
- the tablets comprised 300 mg of Compound I, 18 mg of hydroxypropylmethyl cellulose 2910 as a binder, 18 mg of talc and 1.2 mg of magnesium stearate as lubricants, and 119.8 mg of crospovidone and 90 mg of low-substituted hydroxypropyl cellulose as disintegrants.
- Doses were administered at similar times for each subject in each treatment period. Dosing commenced at approximately 08:30 hours. All subjects fasted from food and fluids (with the exception of water) from 22:00 hours on the day prior to dosing (Day - 1) until breakfast on Day 1 (for subjects receiving Compound I in the fed state (i.e., with food)) or lunch-time on Day 1 (for subjects Compound I in the fasted state), and during the evening prior to the post-study visit until laboratory safety evaluations had been performed on the following day. Water could be consumed at any time during the study, with the exception of the period up to 2 hours post-dose, when no fluids were permitted.
- Total energy content 711 Kcal
- Total fat content 15.72 g (19.9% of total calories)
- Total protein 20.82 g (11.7% total calories)
- AUC o- tz Area under the plasma concentration-time curve (AUC) from time zero up to the last quantifiable concentration (AUC (0-t z )); and AUC o- ⁇ AUC from time zero to infinity
- Pharmacokinetic parameters were log-transformed by analysis and assessed using SAS® Least Square Means derived from a three-way analysis of variance (ANON A) fitting effects for subject, treatment, and period. Treatment comparisons were made by calculating the difference and 95% confidence intervals (CIs) of the difference of the log SAS® Least Square Means between parameters for the respective treatments. The differences and CIs of the differences were back-transformed for reporting purposes.
- SAS® Least Square Means derived from a three-way analysis of variance (ANON A) fitting effects for subject, treatment, and period.
- Treatment comparisons were made by calculating the difference and 95% confidence intervals (CIs) of the difference of the log SAS® Least Square Means between parameters for the respective treatments. The differences and CIs of the differences were back-transformed for reporting purposes.
- the plasma concentration of the active fo ⁇ n of Compound I was determined by the following assay. Plasma samples were isolated from patients treated with Compound I. The plasma samples were treated with sodium hydroxide (Wako Pure Chemical Industries, Ltd.) to convert active forms of Compound I in the plasma to the thiol fo ⁇ n (i.e., Compound II). The plasma sample next was treated with ditl iothreitol (DTT) (Wako Pure Chemical Industries, Ltd.) to prevent the oxidation of thiol groups (i.e., to maintain thiol groups in a reduced state).
- DTT ditl iothreitol
- NEM N-ethylmaleimide
- HPLC High Perfo ⁇ nance Liquid Chromatography
- the absorption of the active fo ⁇ n of Compound I was relatively slow, with the time of maximum observed plasma concentration occurring at between 4 and 5 hours after administration of Compound I. As is apparent from Table 1, the time of maximum observed plasma concentration was similar after administration of Compound I with and without food. Additionally, the half life of the active fo ⁇ n of Compound I was determined to be similar after administration of the drug with and without food.
- CETP activity was substantially similar to the procedures described in Tollefson et al., Methods Enzymol, 129, 797-816 (1986), and Kato et al., J. Biol. Chem., 264, 4082-4087 (1989).
- CETP activity and changes from baseline (pre-dose) were measured, and the resulting data is summarized in Table 2 as percentage change from baseline.
- the mean changes from baseline (pre-dose) in CETP activity over time are set out in the plot of Figure 3.
- CETP activity was much more marked in the fed treatment protocol as compared with the fasted treatment protocol. For example, between 4 and 24 hours post-dose, there is a significant decrease in CETP activity in the fed versus the fasted state. Such a decrease in CETP activity indicates increased bioavailability of the active form of the drug when administered with food as compared to administration of the drag without food.
- Example 2 A clear difference in CETP relative activity was observed when Compound I was administered with and without food, consistent with the results discussed in Example 2. Inhibition of CETP activity was much more marked in the fed treatment protocol as compared with the fasted treatment protocol. For example, between 4 and 24 hours post- dose, there was a significant decrease in CETP activity in the fed versus the fasted state. Specifically, the inhibition of CETP activity following the administration of Compound I with food reached its peak at 6 hours post-administration with 37.6% CETP activity relative to baseline. In contrast, the inhibition of CETP activity following the administration of Compound I without food reached its peak at 8 hours post-administration with 87.8% CETP activity relative to baseline.
- pharmacokinetics parameters such as maximum observed plasma concentration (C max ) and area under the plasma concentration-time curve from time zero to infinity (AUCo- ⁇ ), were affected by administration of Compound I with food.
- C max maximum observed plasma concentration
- AUCo- ⁇ area under the plasma concentration-time curve from time zero to infinity
- the Cma x (mean) value after administration of 600 mg of Compound I was 1.029 ⁇ g/mL when administered with food and only 0.316 ⁇ g/mL when administered without food.
- the AUCo-uc (mean) value after administration of 600 mg of Compound I was 10.458 ⁇ g h/mL when administered with food and only 5.395 ⁇ g h/mL when administered without food.
- the C max and AUCo - ⁇ were about 3 and 2 times higher, respectively, when the patients were administered the drug with food as compared to without food.
- the observed increases in the pharmacokinetic parameters when Compound I is administered with food indicate that the active form of the drug is more readily absorbed when administered with food, such as after a meal.
- the administration of Compound I with food results in an increase in the bioavailability of the active form of the drug when compared to the administration of the drug under fasted conditions.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004222436A AU2004222436A1 (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate |
CA002519458A CA2519458A1 (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
JP2006507671A JP2006520810A (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral absorption of S- [2-([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
BRPI0408442-0A BRPI0408442A (en) | 2003-03-17 | 2004-03-17 | method for increasing the oral bioavailability of s- [2 - ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanothioate |
EP04721354A EP1603554A1 (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
MXPA05009976A MXPA05009976A (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate. |
NO20054739A NO20054739L (en) | 2003-03-17 | 2005-10-14 | Method for increasing oral bioavailability of S-2 '- ("1- (2-ethylbutyl) cyclohexylcarbonylamino) phenyl] -2-methylpropanethioate |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45529303P | 2003-03-17 | 2003-03-17 | |
US60/455,293 | 2003-03-17 | ||
US46052103P | 2003-04-04 | 2003-04-04 | |
US60/460,521 | 2003-04-04 | ||
US47720203P | 2003-06-10 | 2003-06-10 | |
US60/477,202 | 2003-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004082675A1 true WO2004082675A1 (en) | 2004-09-30 |
WO2004082675A8 WO2004082675A8 (en) | 2005-11-03 |
Family
ID=33033150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003589 WO2004082675A1 (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
Country Status (11)
Country | Link |
---|---|
US (2) | US7276536B2 (en) |
EP (1) | EP1603554A1 (en) |
JP (1) | JP2006520810A (en) |
KR (1) | KR20050110017A (en) |
AU (1) | AU2004222436A1 (en) |
BR (1) | BRPI0408442A (en) |
CA (1) | CA2519458A1 (en) |
CO (1) | CO5700729A2 (en) |
MX (1) | MXPA05009976A (en) |
NO (1) | NO20054739L (en) |
WO (1) | WO2004082675A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
US9107836B2 (en) | 2010-11-04 | 2015-08-18 | Hoffmann-La Roche Inc. | Formulation |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
MXPA05009976A (en) * | 2003-03-17 | 2005-11-04 | Japan Tobacco Inc | Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate. |
TWI494102B (en) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20100179214A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
US20100179215A1 (en) * | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
WO2007136741A2 (en) * | 2006-05-19 | 2007-11-29 | Somaxon Pharmaceuticals, Inc. | N-desmethyl-doxepin and methods of using the same to treat sleep disorders |
US8513299B2 (en) | 2006-05-19 | 2013-08-20 | Pernix Sleep, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
US20080058408A1 (en) | 2006-05-19 | 2008-03-06 | Rogowski Roberta L | Low-dose doxepin for treatment of sleep disorders in elderly patients |
US7915307B2 (en) * | 2006-07-20 | 2011-03-29 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
WO2008085567A1 (en) * | 2006-10-04 | 2008-07-17 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
WO2008052139A2 (en) | 2006-10-25 | 2008-05-02 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
US20110077200A1 (en) | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
EP2148659A2 (en) | 2007-04-13 | 2010-02-03 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations |
CA2897420C (en) | 2013-03-27 | 2020-10-27 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
PT3174995T (en) | 2014-07-30 | 2020-10-15 | Hoffmann La Roche | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011710A2 (en) * | 2000-08-03 | 2002-02-14 | Pfizer Products Inc. | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6426365B1 (en) * | 1997-02-12 | 2002-07-30 | Japan Tobacco Inc. | CETP activity inhibitors |
WO2003000295A2 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576830A (en) * | 1966-08-12 | 1971-04-27 | Sumitomo Chemical Co | Amides containing sulfur |
JPS4735786U (en) | 1971-05-10 | 1972-12-20 | ||
US4346277A (en) * | 1979-10-29 | 1982-08-24 | Eaton Corporation | Packaged electrical heating element |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
USRE36481E (en) * | 1986-06-23 | 2000-01-04 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
US4940727A (en) * | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4740438A (en) * | 1986-12-10 | 1988-04-26 | Eastman Kodak Company | Organic disulfides as image dye stabilizers |
US4853319A (en) * | 1986-12-22 | 1989-08-01 | Eastman Kodak Company | Photographic silver halide element and process |
JP2569746B2 (en) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
JPH01278543A (en) | 1988-04-30 | 1989-11-08 | Sanshin Chem Ind Co Ltd | Rubber composition |
JPH01321432A (en) | 1988-06-22 | 1989-12-27 | Konica Corp | Silver halide photographic sensitive material |
JPH0223338A (en) | 1988-07-12 | 1990-01-25 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
US5118583A (en) * | 1988-10-12 | 1992-06-02 | Mitsubishi Paper Mills Limited | Processing composition for printing plate |
DE3835198A1 (en) | 1988-10-15 | 1990-04-19 | Bayer Ag | METHOD FOR PRODUCING RUBBER VULCANISES WITH REDUCED HYSTERESIS LOSSES AND FORM BODIES FROM SUCH VULCANISTS |
FI94339C (en) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
JPH03226750A (en) | 1990-01-31 | 1991-10-07 | Konica Corp | Silver halide color photographic sensitive material |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
FR2665450B1 (en) * | 1990-08-01 | 1994-04-08 | Rhone Poulenc Chimie | PROCESS FOR THE PREPARATION OF AQUEOUS COPOLYMER DISPERSIONS. |
GB9017711D0 (en) | 1990-08-13 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
GB9017710D0 (en) | 1990-08-13 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
GB9120131D0 (en) | 1991-09-20 | 1991-11-06 | Glaxo Group Ltd | Medicaments |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5519001A (en) * | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
EP0618803A4 (en) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments. |
US5217859A (en) * | 1992-04-16 | 1993-06-08 | Eastman Kodak Company | Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings |
US5219721A (en) * | 1992-04-16 | 1993-06-15 | Eastman Kodak Company | Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides |
SG45369A1 (en) * | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
US5350667A (en) * | 1993-06-17 | 1994-09-27 | Eastman Kodak Company | Photographic elements containing magenta couplers and process for using same |
JP3894949B2 (en) * | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | Anti-atherosclerotic diaryl compounds |
AU672699B2 (en) * | 1993-06-30 | 1996-10-10 | Sankyo Company Limited | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
US5446207A (en) * | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
US5459154A (en) * | 1993-11-08 | 1995-10-17 | American Home Products Corporation | N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein |
US5405969A (en) * | 1993-12-10 | 1995-04-11 | Eastman Kodak Company | Manufacture of thioether compounds |
JP3304189B2 (en) * | 1994-03-18 | 2002-07-22 | マツダ株式会社 | Molding rubber composition containing vulcanized scrap rubber and method for producing the same |
US5654134A (en) * | 1994-05-18 | 1997-08-05 | Fuji Photo Film Co., Ltd. | Silver halide emulsion |
DE4428457C1 (en) * | 1994-08-11 | 1995-10-05 | Bayer Ag | Shaped, paraffin contg. mastification agent for synthetic rubbers |
US6001555A (en) | 1994-09-23 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein |
JPH09501186A (en) * | 1994-11-12 | 1997-02-04 | 株式会社エルジ化学 | Cholesteryl ester carrier protein inhibitor peptide and prophylactic and therapeutic agent for arteriosclerosis containing the same |
US5698564A (en) * | 1994-12-16 | 1997-12-16 | Nisshin Flour Milling Co., Ltd. | Diphenyl disulfide compounds |
WO1996030761A1 (en) | 1995-03-27 | 1996-10-03 | Warner-Lambert Company | Method and apparatus for simultaneously testing a plurality of compounds to detect their activity |
JP3296564B2 (en) * | 1995-07-17 | 2002-07-02 | ワーナー−ランバート・コンパニー | Crystalline [R- (R ▲ *, R ▲ *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4 -[(Phenylamino) carbonyl] -1H-pyrrole-1-heptanoic acid hemicalcium salt (atorvastatin) |
JPH0959155A (en) | 1995-08-23 | 1997-03-04 | Kaken Pharmaceut Co Ltd | Cholesteryl ester transfer reaction inhibitor |
DE19610932A1 (en) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-aryl substituted pyridines |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (en) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclically fused pyridines |
US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
AR008789A1 (en) | 1996-07-31 | 2000-02-23 | Bayer Corp | PIRIDINES AND SUBSTITUTED BIPHENYLS |
ES2127690B1 (en) | 1996-08-02 | 2000-01-01 | Univ Granada | PROCEDURES FOR OBTAINING (+) - PUUPEHENONE FROM BICYCLE TERPENOIDS. |
US6121283A (en) | 1996-11-27 | 2000-09-19 | Pfizer Inc | Apo B-secretion/MTP inhibitory amides |
DE19704243A1 (en) | 1997-02-05 | 1998-08-06 | Bayer Ag | New 2-amino-substituted pyridines |
DE19709125A1 (en) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituted quinolines |
JPH10287662A (en) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Fo-5637a and b substance, and their production |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
WO1999014204A1 (en) | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6692909B1 (en) | 1998-04-01 | 2004-02-17 | Whitehead Institute For Biomedical Research | Coding sequence polymorphisms in vascular pathology genes |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
JP2002525350A (en) | 1998-09-25 | 2002-08-13 | モンサント カンパニー | Substituted N-aliphatic-N-aromatic tertiary heteroalkylamines effective for inhibiting cholesterol ester transfer protein activity |
PT1115695E (en) | 1998-09-25 | 2005-10-31 | Monsanto Co | (N + 1) -ALCANOIS 1-AMINOSUBSTITUIDOS (R) -HALOGENATED UIRAL CHIRALS TO INHIBIT THE ACTIVITY OF ESTER TRANSFER PROTEIN OF CHOLESTERYL |
AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
PT1140184E (en) | 1998-12-23 | 2003-10-31 | Searle Llc | COMBINATIONS OF ESTER TRANSFER PROTEIN INHIBITORS OF CHOLESTEROL WITH NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS |
ATE242009T1 (en) | 1998-12-23 | 2003-06-15 | Searle Llc | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND FIBRONIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS |
US6569905B1 (en) | 1998-12-23 | 2003-05-27 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
US20010018446A1 (en) * | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6448295B1 (en) * | 1999-09-23 | 2002-09-10 | G.D. Searle & Co. | Use of substituted N-fused-phenyl-N-benzyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity |
HN2000000203A (en) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED. |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
KR100857759B1 (en) * | 2003-03-17 | 2008-09-09 | 니뽄 다바코 산교 가부시키가이샤 | Pharmaceutical compositions of cetp inhibitors |
MXPA05009976A (en) * | 2003-03-17 | 2005-11-04 | Japan Tobacco Inc | Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate. |
TWI494102B (en) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor |
-
2004
- 2004-03-17 MX MXPA05009976A patent/MXPA05009976A/en not_active Application Discontinuation
- 2004-03-17 CA CA002519458A patent/CA2519458A1/en not_active Abandoned
- 2004-03-17 BR BRPI0408442-0A patent/BRPI0408442A/en not_active IP Right Cessation
- 2004-03-17 EP EP04721354A patent/EP1603554A1/en not_active Withdrawn
- 2004-03-17 JP JP2006507671A patent/JP2006520810A/en not_active Withdrawn
- 2004-03-17 US US10/802,280 patent/US7276536B2/en active Active
- 2004-03-17 AU AU2004222436A patent/AU2004222436A1/en not_active Abandoned
- 2004-03-17 WO PCT/JP2004/003589 patent/WO2004082675A1/en not_active Application Discontinuation
- 2004-03-17 KR KR1020057017446A patent/KR20050110017A/en not_active Application Discontinuation
-
2005
- 2005-10-14 NO NO20054739A patent/NO20054739L/en not_active Application Discontinuation
- 2005-10-14 CO CO05105280A patent/CO5700729A2/en not_active Application Discontinuation
-
2007
- 2007-08-29 US US11/847,085 patent/US20080045599A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6426365B1 (en) * | 1997-02-12 | 2002-07-30 | Japan Tobacco Inc. | CETP activity inhibitors |
WO2002011710A2 (en) * | 2000-08-03 | 2002-02-14 | Pfizer Products Inc. | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
WO2003000295A2 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
Non-Patent Citations (8)
Title |
---|
DE GROOTH, GREETJE J. ET AL: "Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study", CIRCULATION , 105(18), 2159-2165 CODEN: CIRCAZ; ISSN: 0009-7322, 2002, XP002288183 * |
HUANG, ZHIPING ET AL: "Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia", CLINICAL SCIENCE , 103(6), 587-594 CODEN: CSCIAE; ISSN: 0143-5221, 2002, XP002288184 * |
KOBAYASHI, JUNJI ET AL: "Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage", ATHEROSCLEROSIS (SHANNON, IRELAND) , 162(1), 131-135 CODEN: ATHSBL; ISSN: 0021-9150, 2002, XP002288179 * |
OKAMOTO, HIROSHI ET AL: "A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits", NATURE (LONDON) CODEN: NATUAS; ISSN: 0028-0836, vol. 406, 17 June 2000 (2000-06-17), pages 203 - 207, XP002288182 * |
OKAMOTO, HIROSHI ET AL: "Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals", EUROPEAN JOURNAL OF PHARMACOLOGY , 466(1-2), 147-154 CODEN: EJPHAZ; ISSN: 0014-2999, 2003, XP002288185 * |
SHIMOJI EISO ET AL: "Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits.", ATHEROSCLEROSIS. FEB 2004, vol. 172, no. 2, February 2004 (2004-02-01), pages 247 - 257, XP002288186, ISSN: 0021-9150 * |
SHINKAI, HISASHI ET AL: "Bis[2-(Acylamino)phenyl] Disulfides, 2-(Acylamino)benzenethiols, and S-[2-(Acylamino)phenyl] Alkanethioates as Novel Inhibitors of Cholesteryl Ester Transfer Protein", JOURNAL OF MEDICINAL CHEMISTRY , 43(19), 3566-3572 CODEN: JMCMAR; ISSN: 0022-2623, 2000, XP002288180 * |
WATTS, GERALD F.: "The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis", CLINICAL SCIENCE , 103(6), 595-597 CODEN: CSCIAE; ISSN: 0143-5221, 2002, XP002288181 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
US9107836B2 (en) | 2010-11-04 | 2015-08-18 | Hoffmann-La Roche Inc. | Formulation |
Also Published As
Publication number | Publication date |
---|---|
US20080045599A1 (en) | 2008-02-21 |
EP1603554A1 (en) | 2005-12-14 |
WO2004082675A8 (en) | 2005-11-03 |
CO5700729A2 (en) | 2006-11-30 |
NO20054739D0 (en) | 2005-10-14 |
MXPA05009976A (en) | 2005-11-04 |
AU2004222436A1 (en) | 2004-09-30 |
BRPI0408442A (en) | 2006-04-04 |
CA2519458A1 (en) | 2004-09-30 |
NO20054739L (en) | 2005-12-14 |
US7276536B2 (en) | 2007-10-02 |
US20040242683A1 (en) | 2004-12-02 |
KR20050110017A (en) | 2005-11-22 |
JP2006520810A (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080045599A1 (en) | Method for Increasing the Bioavailability of the Active Form of S-[2-([[1-(2-Ethylbutyl)Cyclohexyl]Carbonyl] Amino)Phenyl] 2-Methylpropanethioate | |
US20140121229A1 (en) | Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an hmg coa reductase inhibitor | |
EP1603553B9 (en) | Pharmaceutical compositions of cetp inhibitors | |
EP1467728B1 (en) | Pharmaceutical compositions comprising valsartan and nep inhibitors | |
EP2308490A1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
EP1435968A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
EP1772147A2 (en) | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate | |
KR20080085208A (en) | Combination of triazine derivatives and hmg-coa reductase inhibitors for the treatment of diabetes | |
KR20070074549A (en) | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
ZA200508160B (en) | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate | |
JP2005515984A (en) | Pharmaceutical composition having a combination of metformin and 4-oxobutanoic acid and its application in the treatment of diabetes | |
CN112512526B (en) | Application of combination of compound A and compound B in preparation of medicine for treating gout or hyperuricemia | |
RU2318504C2 (en) | Cetp-inhibitor-containing pharmaceutical compositions | |
AU2013203476C1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 170750 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501652 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/009976 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2519458 Country of ref document: CA Ref document number: 1020057017446 Country of ref document: KR Ref document number: 2006507671 Country of ref document: JP Ref document number: 2004222436 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048074442 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721354 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004222436 Country of ref document: AU Date of ref document: 20040317 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 542853 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2004222436 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/08160 Country of ref document: ZA Ref document number: 200508160 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501486 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05105280 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2664/CHENP/2005 Country of ref document: IN Ref document number: 2005131951 Country of ref document: RU |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057017446 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721354 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0408442 Country of ref document: BR |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004721354 Country of ref document: EP |